Combination therapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer).
- Your cancer must have spread to other parts of the body (like the liver or lungs) or come back after initial treatment.
- You either have not had any previous cancer treatment or you have received only gemcitabine-based chemotherapy and your cancer got worse.
- You need to be in good physical condition (able to do light housework or office work).
- Your liver and kidney function must be within acceptable limits (based on blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines the immunotherapy drug sintilimab with chemotherapy and radiation for people with inoperable locally advanced pancreatic cancer who have not received prior systemic treatment. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This study tests a combination of three drugs—two pills and one infusion—for people with advanced pancreatic cancer who have already tried one or more treatments. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a new medicine (IBI363) combined with chemotherapy for people with advanced pancreatic cancer that has grown after their first treatment. The goal is to see if this combination can help shrink or control the cancer longer.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.